Pacific Biosciences of California Inc(PACB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 7:20 PM ET (Korea 10/28 08:20)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.43 | Insider Own | 8.56% | Shs Outstand | 310.8M | Perf Week | 25% |
| Market Cap | 0.76B | Forward P/E | - | EPS next Y | 5.29% | Insider Trans | -2.52% | Shs Float | 284.2M | Perf Month | 43.27% |
| Enterprise Value | 1.23B | PEG | - | EPS next Q | -0.13 | Inst Own | 53.87% | Short Float | 16.51% | Perf Quarter | 75% |
| Income | -0.13B | P/S | 4.78 | EPS this Y | 74.02% | Inst Trans | 1.08% | Short Ratio | 4.25 | Perf Half Y | 55.06% |
| Sales | 0.16B | P/B | - | EPS next 5Y | 41.41% | ROA | -16.66% | Short Interest | 46.93M | Perf YTD | 31.02% |
| Book/sh | -0.11 | P/C | 3.21 | EPS past 3/5Y | -9.18% - | ROE | -929.32% | 52W High | -28.68% ($3.43) | Perf Year | 17.22% |
| Cash/sh | 0.76 | P/FCF | - | Sales past 3/5Y | 7.64% 15.19% | ROIC | -19.56% | 52W Low | 128.97% ($1.07) | Perf 3Y | -65.54% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 75.85% | Gross Margin | 34.29% | Volatility(W/M) | 11.56% 14.01% | Perf 5Y | -90.4% |
| Dividend TTM | - | EV/Sales | 7.73 | Sales Y/Y TTM | 2.02% | Oper. Margin | -101.67% | ATR (14) | 0.23 | Perf 10Y | -71.18% |
| Dividend Ex-Date | - | Quick Ratio | 4.03 | EPS Q/Q | -3.08% | Profit Margin | -82.49% | RSI (14) | 63.28 | Recom | 2.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.92 | Sales Q/Q | -1.91% | SMA20 | 8.94% ($2.25) | Beta | 2.24 | Target Price | $2.54 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/4 | SMA50 | 41.09% ($1.74) | Rel Volume | 1.69 | Prev Close | $2.25 |
| Employees | 485 | LT Debt/Eq | - | EPS/Sales Surpr. | - -2.31% | SMA200 | 53.04% ($1.6) | Avg Volume(3M) | 11.04M | Price | $2.45 |
| IPO | 2010/10/27 | Option/Short | Yes/Yes | Trades | 21710 | Volume | 18,653,131 | Change | 8.89% |
🧬 Pacific Biosciences PACB is a U.S. genomics analysis equipment company that develops and supplies a high-precision HiFi long-read genomic sequencing platform. It provides instruments and consumables for a wide range of research and clinical areas, including human genomics, plants and animals, infectious diseases, and oncology. Its key technological differentiator is the ability to detect structural variations and complex genomic regions with high accuracy.
Over the past 1 year, roughly in the middle
29% below its 1-year high.
Traded more than usual. That is 169% of its average volume.
Next earnings report: November 4
8 days to go.
PACB has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +74.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $478. Peers typically go for $336.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -90.4%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 53.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #51 of 142 in the industry
Based on market cap of $762M.
AHCO#47 AdaptHealth Corp $798M PER - 
VREX#48 Varex Imaging Corp $783M PER 35.4 
INMD#49 Inmode Ltd $781M PER 11.0 
CTKB#50 Cytek BioSciences Inc $777M PER - PACB#51 Pacific Biosciences of California Inc $762M PER - 
FAQ
What kind of company is PACB?
PACB belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of PACB?
The market cap of PACB is approximately $762M, ranking 2,797 within its sector.
What is the 52-week high and low for PACB?
PACB has recorded a 52-week high of $3.43 and a low of $1.07.
